Reduced levels of mature NGF available to the basal forebrain precede the loss of cholinergic neurons and the impaired cognitive functions observed in Alzheimer's disease (AD) (Alzheimer, Stelzmann, Schnitzlein, & Murtagh, 1995), thus making NGF an important contributor to neuronal survival (Hefti & Mash, 1989; Niewiadomska, Mietelska‐Porowska, & Mazurkiewicz, 2011) and useful as a therapeutic agent in AD (Cattaneo & Calissano, 2012; Iulita & Cuello, 2015). The gene discussed is NGF; the disease is early-onset autosomal dominant Alzheimer disease.